At the Ninth Vaccine & International Society of Vaccines Congress in Seoul, Vaxart Inc. representatives presented positive results from two vaccine studies, an oral norovirus vaccine and an H1N1 influenza tablet.
“The first presentation covered data demonstrating that Vaxart’s oral norovirus vaccine elicited a broader immune response when compared to an injectable VLP VP1 vaccine,”
Vaxart Chief Executive Officer Wouter Latour said. “The second presentation highlighted data from a recent Phase 1 clinical study demonstrating that Vaxart’s H1N1 influenza tablet vaccine generated neutralizing antibodies in 92 percent of subjects after a single dose.”
Vaxart developed temperature-stable tablets that can be shipped and stored without needing refrigeration. Tablets make it easier to distribute and gets rid of injectable vaccines, which can cause needle stick injury and medical waste.
“Vaxart’s lead programs include tablet vaccine candidates for seasonal influenza, norovirus and Respiratory Syncytial Virus. The vaccines are based on a versatile vector-based platform that is designed to be suitable for a wide range of infectious diseases,” Latour
said.
